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As an important global health challenge, diarrhea kills nearly two million
people each year. Postinfectious irritable bowel syndrome (IBS) usually manifests
itself as the diarrhea-predominant subtype. Small intestinal bacterial overgrowth has
been observed more frequently in patients with IBS compared to healthy controls.
However, the pathophysiology of IBS is not fully understood, and based on recent
evidences, altered gut microbiota is involved in the pathogenesis of IBS. Therefore, we
aimed to compare the microbiome in hospitalized patients with diarrhea and healthy
individuals. Thirty patients and 10 healthy controls were included into this case–
control study. Microbial count was performed using quantitative real-time polymerase
chain reaction method using bacterial 16S rRNA gene. Clostridium cluster IV and
Bacteroideswere significantly more frequent in the patients compared with the healthy
individuals (p= 0.02 and 0.023, respectively). However, the quantity of Enterococcus
and Bifidobacterium groups were significantly higher in healthy controls than in
diarrheal group (p= 0.000076 and 0.001, respectively). The results showed that the
number of bacteria in all bacterial groups was significantly different between healthy
individuals and diabetic group, whereas the difference between the healthy group and
IBS was not significant for Bifidobacterium group. The findings of this study outlined
the relationship between diarrhea, IBS, and diabetes disease and bacterial composition.
It could be concluded that modifying the bacterial composition by probiotics can be
helpful in the control and management of the mentioned disease.
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Introduction
Recent reports focused on the reality of a positive relationship between
human health and the microbial flora that colonize the human gut. Among the gut
bacteria, which behave as a functional human organ, probiotics represent the Holy
Grail because they are related to a broad spectrum of positive effects on host
health, including positive effects on host longevity [1]. As a functional gastroin-
testinal (GI) disorder, irritable bowel syndrome (IBS) is characterized by abdomi-
nal pain and changes in the pattern of bowel movements associated with bowel
habit change such as diarrhea and constipation without any evidence of underlying
damage [2, 3]. Although IBS is not known as a serious disorder, 10%–15% of the
adult population in the developed world has been observed affected with the
disorder; however, the pooled prevalence of IBS varies considerably, both by
geographical location and by applied diagnostic criteria [4–6]. It is more common
in South America and less common in Southeast Asia and the high prevalence of
IBS is joined by vast societal monetary burdens and negative impacts on the
quality of life in the afflicted individuals with the disorder [7, 8]. IBS does not lead
to dangerous conditions in most patients, but can be associated with increased side
effects such as chronic pain and fatigue and reduced work productivity [9, 10].
Researchers have reported that the high incidence of IBS together with the
associated comorbidities can increase social costs and can also greatly affect the
patient’s quality of life [8, 11].
Although the pathophysiology of IBS is not fully understood, several
hypotheses have been proposed. Acute GI infections increase the risk of developing
and expanding IBS. Prolonged fever, anxiety, and depression are the other factors
that increase the likelihood of developing the syndrome. The biochemical signaling
taken place between the GI tract and the central nervous system (the brain–gut axis)
has been accepted as the major pathogenetic mechanism of IBS, which suggests that
IBS occurs due to disturbances in the interoperability of the brain-intestinal axis and
is correlated with a dysfunction of the GI autonomic nervous system [4]. Other
theories including gut motility disorders, pain sensitivity, infections including small
intestinal bacterial overgrowth, neurotransmitters, genetic factors, and food sensi-
tivity have also known as the causes of the disorder [12].
Despite the considerable burden of IBS, treatment alternatives stay restricted
and look into the etiology, and pathophysiology of this multifactorial disorder is
continuous [13]. The growing evidences have indicated that IBS might present due
to other potential mechanisms including gut microbiota and low-grade inflamma-
tion/immune activation [14, 15]. Comparisons of IBS patients with healthy
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participant in several lines of literatures have shown that the microbiota differs
significantly between groups, which demonstrate the putative role of gut micro-
biota in IBS [16, 17]. Postinfectious IBS; colonic fecal microbiota transplantation;
and therapeutic effects of probiotics, prebiotics, synbiotics, and non-systemic anti-
microbials have also supported the contribution of the gut microbiota to the
pathophysiology of IBS [18–23].
Given the evidence that approximately 10% of IBS patients’ symptoms
began following an episode of infectious diarrhea and based on our knowledge of
the relationship between alteration of gut microbiota and inflammation of gut, we
encouraged to compare the microbiome in hospitalized patients with diarrhea and
healthy individuals.
Materials and Methods
Participant and sampling
Thirty affected hospitalized participants with diarrhea (age: 56± 8 years)
who referred to Institute of Endocrinology and Metabolism Research and Training
Center, Iran University of Medical Sciences in Tehran, Iran were recruited into the
study as the case group. Twenty non-diarrheal individuals, matched for age,
gender, and their current living environment were recruited as the healthy
participants. Stool samples from the patients and healthy individuals were
collected. Sterile cups were used to instant stool sampling after defecation and
brought to the laboratory within 2 h. Collected stool samples were instantly stored
in microbiology laboratory at – 70 °C upon arrival.
Pregnancy, lactation, organic GI disease, severe systematic disease, major or
complicated abdominal surgery, severe endometriosis, and dementia were the
exclusion criteria for patients, and intestinal disturbances (including lactose
intolerance and celiac disease), ongoing antibiotic treatment, and all exclusion
criteria of the patients were considered as the exclusion criteria for controls.
This study was approved by research ethics committees of Iran University of
Medical Sciences and according to Declaration of Helsinki. A signed informed
consent form was received from each of the participant and they were ensured
anonymity of all information.
DNA extraction
An amount of 200 mg of each fecal sample was used for bacterial total DNA
extraction. Extraction of total DNA from all stool specimens was performed using
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QIAamp® DNA Stool Mini Kit (Qiagen Retsch GmbH, Hannover, Germany)
according to the manufacturer’s instruction. Quality and quantity of the extracted
DNA was measured by Nanodrop spectrophotometer (Nanodrop Technologies,
Wilmington, DE, USA) and the DNA integrity was assessed by 1% agarose
gel-electrophoresis. Finally, entire extracted DNA samples were immediately
transferred into −20 °C storage.
Microbial quantification by real-time polymerase chain reaction (PCR)
Briefly, all bacterial 16S rRNA sequences were extracted from SILVA High
Quality Ribosomal RNA database [30], then converted into 16S rDNA, and
specific probe and primer sequences were designed in several steps using various
databases including NCBI, probebase, IDT and EMBL-EBI, and also AlleleID
software (version 7.5, Humana Press, USA). Characteristics of primers and
TaqMan probes are demonstrated in Table I.
Using 16S rDNA gene-specific primers and probes, amplification of target 16s
rDNA was performed in Rotor-Gene 6000 real-time PCR cycler (Qiagen Corbett,
Hilden, Germany) by real-time TaqMan quantitative PCR (qPCR). Each reaction
mixture in a total volume of 20 μl, which contained 0.5 μl of forward primer, 0.5 μl
of reverse primer, 0.5 μl of TaqMan probe, 12 μl of Probe Ex Taq (probe qPCR)
Master Mix (Takara Bio, Shiga, Japan), 1 μl of template DNA, and 5.5 μl sterilized
ultrapure water, was run to amplify the target region under following real-time
qPCR cycling condition: an initial holding at 95 °C for 30s, followed by 40 cycles of
denaturation at 95 °C for 5s, and annealing/extension at 60 °C for 30s. No template
reaction was used as the negative control. Bifidobacterium bifidum ATCC 29521,
Lactobacillus acidophilus ATCC 4356, and Fusobacterium nucleatum ATCC
25586 were provided from the American Type Culture Collection (ATCC) and
were used as the bacterial standard strains. All qPCR runs were carried out in
triplicate, and averaged numbers were used for calculation and analysis.
Bacterial count
Determination of the number of Lactobacillus, Bifidobacterium, Fusobac-
terium, and Prevotella groups in each sample was performed after construction of
standard curves based on 10-fold serial dilutions of bacterial standard strains
genomic DNA of known concentration from pure cultures, corresponding to
101–1010 copies per gram feces. According to Applied Biosystems tutorials,
standard curves were created and were normalized to the copy number of the 16S
rRNA gene for each species. If there was a copy number-unknown species of
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16S rRNA operon, average operon numbers of the closest bacterial taxa obtained
from the ribosomal RNA database rrnDB was used as the operon copy number.
The threshold cycle values (Ct) obtained from the standard curves were applied to
determine bacterial copy number per gram stool.
Sample size and statistical analysis
SPSS version 20.0 software (SPSS Inc., Chicago, IL, USA) and Minitab
version 16.2.0 (State College, PA, USA) were used for statistical analysis.
According to a predicted difference of at least 2 × 105 copies per gram of feces
in the mean bacterial numbers between the healthy individuals and patients, the
sample size of 20 subjects provided the sufficient power (80%), considering a type
I error of 0.05 and effect size of 0.4176. For group comparison, independent
sample t-test was used and the Pearson’s correlation was assessed for linear
correlation analysis. A p< 0.05 was considered statistically significant. All the
descriptive data have been expressed as mean± standard deviation. The Kolmo-
gorov–Smirnov test was applied to test for a normal distribution.
Results
Participants
Thirty participants with diarrhea with the mean age of 56± 8 years and 10
healthy individuals with the mean age of 51± 4 years were recruited to the study;
14 participants with diarrhea were males and 16 were females. Healthy individuals
included 4 males and 7 females.
qPCR analysis of bacterial groups
This case–control study qPCR analysis was aimed to assess the differences in
composition of fecal microbiota in patients with diarrhea and healthy participant for
four groups of bacteria including Bacteroides,Clostridium cluster IV, Enterococcus,
and Bifidobacterium groups. As indicated in Table II, the results showed that fecal
microbiota in diarrheal cases and healthy individuals were significantly different for
all the studied bacterial groups. Clostridium cluster IV and Bacteroides were
significantly more frequent in the patients compared with the healthy individuals
(p= 0.02 and 0.023, respectively). However, the quantity of Enterococcus and
Bifidobacterium groups was significantly higher in healthy controls than in diarrheal
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group (p= 0.000076 and 0.001, respectively). Differences of intestinal bacterial
genera in the study groups were represented in Table II and Figure 1.
The correlations between concentration of the bacterial species in
healthy–diabetic and healthy–IBS groups
Some of the participants in this study had background diseases of diabetes and
IBS; therefore, the correlation or, in other words, the difference in bacterial groups
between healthy individuals and those with any of the mentioned diseases was
investigated. The results showed that the number of bacteria in all bacterial groups
was significantly different between healthy individuals and diabetic group, whereas
the difference between the healthy group and IBS was not significant for Bifido-
bacterium group. The mean quantity of Bacteroides, Clostridium cluster IV, and
Bifidobacterium groups was significantly higher in diabetic group than in non-
diabetic individuals (p= 0.000043, p= 0.001, and p< 0.001, respectively). Bacter-
oides, Clostridium cluster IV, and Bifidobacterium were also significantly more
frequent in the IBS patients compared with the healthy individuals (p= 0.035,
0.006, and 0.052, respectively). Bacteroides concentration was higher both in
Figure 1. Bacterial groups quantified by real-time PCR and expressed as copy number of bacterial
groups per gram stool in human adults with diarrhea (red boxes; N= 10), IBS (blue boxes; N= 10),
diabetes (green boxes; N= 10), and healthy controls (orange boxes; N= 10). Boxes show the upper
(75%) and the lower (25%) percentiles of the data. Whiskers indicate the highest and the smallest
values. *Outlier points
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diabetic group and IBS patients than in healthy group (p= 0.000011 and 0.000042,
respectively). The correlations between concentration of the bacterial species in
healthy–diarrheal, healthy–diabetic, and healthy–IBS groups have been indicated.
Discussion
Correlation between imbalance normal microbial community and GI con-
ditions such as inflammatory bowel disease and IBS, and wider systemic
manifestations of disease such as obesity, type 2 diabetes, and atopy have
previously been reported in several reports [6, 13, 14]. Although intensive research
over the past two decades has been carried to find the etiology of IBS, its
pathophysiology remains poorly understood [19]. Diarrhea, constipation, or mixed
type are the symptoms of IBS. Based on this knowledge, we hypothesized that
intestinal microbiota composition in patients with diarrhea is different from
healthy control participant. In this study, the number of four groups of bacteria
including Bacteroides, Clostridium cluster IV, Enterococcus, and Bifidobacterium
was measured using qPCR in patients and healthy participants. Our data showed
that fecal microbiota in diarrheal cases and healthy individuals were significantly
different for all the studied bacterial groups.
In comparison to healthy controls, our data showed that the copy number of
Bacteroides and Clostridium cluster IV group was significantly higher in partici-
pants with diarrhea. In contrast with this study, Swidsinski et al. [24] using
fluorescence in situ hybridization analysis (FISH) demonstrated that the fecal
microbiota in idiopathic diarrhea was markedly different, marked by reduction in
concentrations of habitual Eubacterium rectale, Bacteroides, and Faecalibacterium
prausnitzii groups. Using FISH analysis, a study conducted on patients by
Soko et al. also showed that a reduction of a major member of Firmicutes,
F. prausnitzii, is associated with a higher risk of postoperative recurrence of ileal
Crohn’s disease (CD). They found that F. prausnitzii exhibits anti-inflammatory
effects, partly due to secreted metabolites able to block NF-κB activation and
IL-8 production; therefore, counterbalancing dysbiosis using F. prausnitzii as a
probiotic can be a promising strategy in CD treatment [25].
In addition to the diarrhea, which is designated as the principal diagnosis,
some patients also have underlying diseases of diabetes and IBS. Therefore, we
also decided to evaluate the association of each of the studied bacterial group with
the underlying diseases. In agreement with findings of Vrakas et al. [26],
Maukonen et al. [27], and Rajilic´-Stojanovic´ et al. [28], our observation showed
that the concentrations of Clostridium cluster IV and Fusobacterium groups were
relatively higher in the IBS group compared to the healthy participant.
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Consistently, Kerckhoffs et al. [29] showed that bifidobacteria levels in both fecal
and duodenal brush samples of IBS patients were significantly lower (6± 0.6 vs.
19± 2.5, p< 0.001) compared to healthy participants, which indicate a role for
microbiotic composition in IBS pathophysiology. They analyzed fecal samples for
the composition of the total microbiota using FISH and analyzed both fecal and
duodenal brush samples for the composition of bifidobacteria using qPCR.
Similarly, Rajilic´-Stojanovic´ et al. [28] and Si et al. [30] showed meaningful
lower concentration of Bifidobacterium in IBS patients compared to the controls.
In this study, we found that the level of Enterococcus group was significantly
lower in the patients with IBS compared to the healthy group. This observation
was in contrast with the findings of Zhuang et al. [31].
In line with our results, the study conducted by Rajilic´-Stojanovic´, the
intestinal microbiota including a twofold increased ratio of Bacteroidetes
(p= 0.0002), approximately 1.5-fold increase in numbers of Clostridium spp.
(p= 0.005); a twofold decrease in the number of Bacteroidetes (p= 0.0001); a
1.5-fold decrease in numbers of Bifidobacterium and Faecalibacterium spp.
(p= 0.05), of IBS patients differed significantly (p= 0.0005) from that of controls
[28]. Characterization of the fecal microbiota using high-throughput sequencing of
the 16S rRNA gene showed a significant increase of Bacteroidetes and Proteo-
bacteria in the IBS group compared to the healthy participants [32]. Other report
also confirmed our data and demonstrated that the mucosa-associated microbiota
in patients with IBS is significantly different from healthy controls with increases
in bacteroides and clostridia and a reduction in bifidobacteria in patients with
IBS-D [33]. However, global and deep molecular analysis of microbiota signa-
tures in fecal samples from patients with IBS disclosed a twofold decrease in the
number of Bacteroidetes [33]. In this study, the level of Bifidobacteriumwas lower
in IBS patients than controls, but this difference was not statistically significant.
This study revealed that the level of Bacteroides, Bifidobacterium, and
Clostridium cluster IV in patients with underlying disease of diabetes was
significantly higher compared with those in their healthy counterparts. Micro-
biome profile showed a high level of Enterococcus group in healthy participant
than individuals with diabetes. On the contrary to this study, Remely et al. [34] and
Sedighi et al. [6] found no significant differences in copy number of genus
Bifidobacterium between the case and control groups; nonetheless, Murri et al.
[35] reported a significant decrease in the number of Bifidobacterium in the
children with diabetes. Consistent with our findings, Larsen et al. [36] found that
the ratio of Bacteroidetes was increased in diabetes’ cases; however, Lambeth
et al. [37] did not observe differences in the abundances of phyla Bacteroidetes.
On the contrary to this study, data reported by Remely et al. [34] and Larsen et al.
[36] showed no significant difference in the level of Clostridium cluster IV
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between patients with diabetes and healthy individuals. It is previously reported that
total cholesterol and low-density lipoprotein cholesterol reduction are associated with
dairy products enriched with Enterococcus faecium in participant having a normal
lipid profile and participant with medium to moderate hypercholesterolemia [38].
Although participants included in this study were matched for age, gender,
race, living environment, and non-interventions of medications and foods, which
may affect the outcomes (such as different antibiotics, prebiotics, and probiotics),
our findings were not completely consistent with previous reports, and controver-
sial results regarding the dysbiosis of the gut microbiota in hospitalized patients
with diarrhea as well as contradictory findings on the relationship between various
bacterial groups and IBS and diabetes were observed. This discrepancy might be
due to heterogeneity in various factors such as genetic background, ethnicity,
geographical location, environmental and occupational exposures, medical history,
possible underlying diseases/disorders, lifestyle, and diet habits of participant
across studies. Non-significance in some of our results may have been related to a
relatively small sample size.
On the whole, the results of this study indicate that diarrhea and the
underlying disorders of IBS and diabetes in humans are associated with compo-
sitional changes in intestinal microbiota; however, we cannot conclude about the
causality of this dysbiosis. Further studies are suggested to determine if microbial
imbalance causes these medical conditions or changes in microbiota profile are a
reflection of the disease state. Overall, it could be concluded that modifying the
bacterial composition by probiotics can be helpful in the control and management
of the mentioned disease.
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